Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 3/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606027 | 0.93 | CDK9 (0.43) | PRPS1HRH4JAK2JAK1TERT | |
| SCHEMBL12057245 | 0.91 | PRPS1 (0.48) | PRPS1CDK9 | |
| SCHEMBL605371 | 0.85 | HRH4 (0.57) | HRH4KCNH2 | |
| SCHEMBL4169750 | 0.84 | CDK9 (0.43) | PRPS1CDK9 | |
| SCHEMBL604696 | 0.83 | HRH4 (0.49) | HRH4TERT | |
| SCHEMBL605460 | 0.83 | HRH4 (0.56) | HRH4KCNH2 | |
| SCHEMBL604094 | 0.83 | HRH4 (0.44) | PRPS1HRH4JAK2JAK1CDK9 | |
| SCHEMBL606701 | 0.82 | HRH4 (0.52) | HRH4PARP1 | |
| SCHEMBL605587 | 0.79 | HRH4 (0.57) | PRPS1HRH4CDK9KCNH2 | |
| SCHEMBL3476731 | 0.77 | HRH4 (0.49) | HRH4JAK2JAK1CDK9DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | claimed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | claimed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| WO-2009079001-A1 | BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | PRPS1 2710/4885HRH4 1308/4885JAK2 871/4885 |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | PRPS1 3948/4885HRH4 1/4885JAK2 929/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | PRPS1 2185/4885HRH4 3260/4885JAK2 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.